期刊
ANNALS OF NEUROLOGY
卷 67, 期 4, 页码 498-507出版社
WILEY
DOI: 10.1002/ana.21935
关键词
-
资金
- National Multiple Sclerosis Society [PP1028, JF2116, RG3812]
- NIH. NINDS [K24 NS044250-01]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K24NS044250, R01NS037513] Funding Source: NIH RePORTER
Objective: To determine if suppressing Nogo-A, an axonal inhibitory protein, will promote functional recovery in a murine model of multiple sclerosis (MS). Methods: A small interfering RNA was developed to specifically suppress Nogo-A (siRNA-NogoA). The siRNA-NogoA silencing effect was evaluated in vitro and in vivo via immunohistochemistry. The siRNA was administered intravenously in 2 models of experimental autoimmune encephalomyelitis (EAE). Axonal repair was measured by upregulation of GAP43. Enzyme-linked immunosorbent assay, flow cytometry, and H-3-thymidine incorporation were used to determine immunological changes in myelin-specific T cells in mice with EAE. Results: The siRNA-NogoA suppressed Nogo-A expression in vitro and in vivo. Systemic administration of siRNA-NogoA ameliorated EAE and promoted axonal repair, as demonstrated by enhanced GAP43+ axons in the lesions. Myelin-specific T-cell proliferation and cytokine production were unchanged in the siRNA-NogoA-treated mice. Interpretation: Silencing Nogo-A in EAE promotes functional recovery. The therapeutic benefit appears to be mediated by axonal growth and repair, and is not attributable to changes in the encephalitogenic capacity of the myelin-specific T cells. Silencing Nogo-A may be a therapeutic option for MS patients to prevent permanent functional deficits caused by immune-mediated axonal damage. ANN NEUROL 2010;67:498-507
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据